Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15

Pneumococcal conjugate vaccine (PCV) and Haemophilus influenzae type b (Hib) vaccine are now used in most countries. To monitor global and regional progress towards improving child health and to inform national policies for disease prevention and treatment, we prepared global, regional, and national...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet global health Vol. 6; no. 7; pp. e744 - e757
Main Authors: Wahl, Brian, O'Brien, Katherine L, Greenbaum, Adena, Majumder, Anwesha, Liu, Li, Chu, Yue, Lukšić, Ivana, Nair, Harish, McAllister, David A, Campbell, Harry, Rudan, Igor, Black, Robert, Knoll, Maria Deloria
Format: Journal Article
Language:English
Published: England Elsevier Ltd 01.07.2018
Elsevier
Subjects:
Child, Preschool
Global Health - statistics & numerical data
Haemophilus Infections - epidemiology
Haemophilus influenzae type b
Humans
Infant
Pneumococcal Infections - epidemiology
Streptococcus pneumoniae
Vaccines, Conjugate
ISSN:2214-109X, 2214-109X
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Pneumococcal conjugate vaccine (PCV) and Haemophilus influenzae type b (Hib) vaccine are now used in most countries. To monitor global and regional progress towards improving child health and to inform national policies for disease prevention and treatment, we prepared global, regional, and national disease burden estimates for these pathogens in children from 2000 to 2015. Using WHO and Maternal and Child Epidemiology Estimation collaboration country-specific estimates of pneumonia and meningitis mortality and pneumonia morbidity from 2000 to 2015, we applied pneumococcal and Hib cause-specific proportions to estimate pathogen-specific deaths and cases. Summary estimates of the proportion of pneumonia deaths and cases attributable to these pathogens were derived from four Hib vaccine and six PCV efficacy and effectiveness study values. The proportion of meningitis deaths due to each pathogen was derived from bacterial meningitis aetiology and adjusted pathogen-specific meningitis case–fatality data. Pneumococcal and Hib meningitis cases were inferred from modelled pathogen-specific meningitis deaths and literature-derived case–fatality estimates. Cases of pneumococcal and Hib syndromes other than pneumonia and meningitis were estimated using the ratio of pathogen-specific non-pneumonia, non-meningitis cases to pathogen-specific meningitis cases from the literature. We accounted for annual HIV infection prevalence, access to care, and vaccine use. We estimated that there were 294 000 pneumococcal deaths (uncertainty range [UR] 192 000–366 000) and 29 500 Hib deaths (18 400–40 700) in HIV-uninfected children aged 1–59 months in 2015. An additional 23 300 deaths (15 300–28 700) associated with pneumococcus and fewer than 1000 deaths associated Hib were estimated to have occurred in children infected with HIV. We estimate that pneumococcal deaths declined by 51% (7–74) and Hib deaths by 90% (78–96) from 2000 to 2015. Most children who died of pneumococcus (81%) and Hib (76%) presented with pneumonia. Less conservative assumptions result in pneumococcccal death estimates that could be as high as 515 000 deaths (302 000–609 000) in 2015. Approximately 50% of all pneumococcal deaths in 2015 occurred in four countries in Africa and Asia: India (68 700 deaths, UR 44 600–86 100), Nigeria (49 000 deaths, 32 400–59 000), the Democratic Republic of the Congo (14 500 deaths, 9300–18 700), and Pakistan (14 400 deaths, 9700–17 000]). India (15 600 deaths, 9800–21 500), Nigeria (3600 deaths, 2200–5100), China (3400 deaths, 2300–4600), and South Sudan (1000 deaths, 600–1400) had the greatest number of Hib deaths in 2015. We estimated 3·7 million episodes (UR 2·7 million–4·3 million) of severe pneumococcus and 340 000 episodes (196 000–669 000) of severe Hib globally in children in 2015. The widespread use of Hib vaccine and the recent introduction of PCV in countries with high child mortality is associated with reductions in Hib and pneumococcal cases and deaths. Uncertainties in the burden of pneumococcal disease are largely driven by the fraction of pneumonia deaths attributable to pneumococcus. Progress towards further reducing the global burden of Hib and pneumococcal disease burden will depend on the efforts of a few large countries in Africa and Asia. Bill & Melinda Gates Foundation.
AbstractList Pneumococcal conjugate vaccine (PCV) and Haemophilus influenzae type b (Hib) vaccine are now used in most countries. To monitor global and regional progress towards improving child health and to inform national policies for disease prevention and treatment, we prepared global, regional, and national disease burden estimates for these pathogens in children from 2000 to 2015. Using WHO and Maternal and Child Epidemiology Estimation collaboration country-specific estimates of pneumonia and meningitis mortality and pneumonia morbidity from 2000 to 2015, we applied pneumococcal and Hib cause-specific proportions to estimate pathogen-specific deaths and cases. Summary estimates of the proportion of pneumonia deaths and cases attributable to these pathogens were derived from four Hib vaccine and six PCV efficacy and effectiveness study values. The proportion of meningitis deaths due to each pathogen was derived from bacterial meningitis aetiology and adjusted pathogen-specific meningitis case-fatality data. Pneumococcal and Hib meningitis cases were inferred from modelled pathogen-specific meningitis deaths and literature-derived case-fatality estimates. Cases of pneumococcal and Hib syndromes other than pneumonia and meningitis were estimated using the ratio of pathogen-specific non-pneumonia, non-meningitis cases to pathogen-specific meningitis cases from the literature. We accounted for annual HIV infection prevalence, access to care, and vaccine use. We estimated that there were 294 000 pneumococcal deaths (uncertainty range [UR] 192 000-366 000) and 29 500 Hib deaths (18 400-40 700) in HIV-uninfected children aged 1-59 months in 2015. An additional 23 300 deaths (15 300-28 700) associated with pneumococcus and fewer than 1000 deaths associated Hib were estimated to have occurred in children infected with HIV. We estimate that pneumococcal deaths declined by 51% (7-74) and Hib deaths by 90% (78-96) from 2000 to 2015. Most children who died of pneumococcus (81%) and Hib (76%) presented with pneumonia. Less conservative assumptions result in pneumococcccal death estimates that could be as high as 515 000 deaths (302 000-609 000) in 2015. Approximately 50% of all pneumococcal deaths in 2015 occurred in four countries in Africa and Asia: India (68 700 deaths, UR 44 600-86 100), Nigeria (49 000 deaths, 32 400-59 000), the Democratic Republic of the Congo (14 500 deaths, 9300-18 700), and Pakistan (14 400 deaths, 9700-17 000]). India (15 600 deaths, 9800-21 500), Nigeria (3600 deaths, 2200-5100), China (3400 deaths, 2300-4600), and South Sudan (1000 deaths, 600-1400) had the greatest number of Hib deaths in 2015. We estimated 3·7 million episodes (UR 2·7 million-4·3 million) of severe pneumococcus and 340 000 episodes (196 000-669 000) of severe Hib globally in children in 2015. The widespread use of Hib vaccine and the recent introduction of PCV in countries with high child mortality is associated with reductions in Hib and pneumococcal cases and deaths. Uncertainties in the burden of pneumococcal disease are largely driven by the fraction of pneumonia deaths attributable to pneumococcus. Progress towards further reducing the global burden of Hib and pneumococcal disease burden will depend on the efforts of a few large countries in Africa and Asia. Bill & Melinda Gates Foundation.
Background: Pneumococcal conjugate vaccine (PCV) and Haemophilus influenzae type b (Hib) vaccine are now used in most countries. To monitor global and regional progress towards improving child health and to inform national policies for disease prevention and treatment, we prepared global, regional, and national disease burden estimates for these pathogens in children from 2000 to 2015. Methods: Using WHO and Maternal and Child Epidemiology Estimation collaboration country-specific estimates of pneumonia and meningitis mortality and pneumonia morbidity from 2000 to 2015, we applied pneumococcal and Hib cause-specific proportions to estimate pathogen-specific deaths and cases. Summary estimates of the proportion of pneumonia deaths and cases attributable to these pathogens were derived from four Hib vaccine and six PCV efficacy and effectiveness study values. The proportion of meningitis deaths due to each pathogen was derived from bacterial meningitis aetiology and adjusted pathogen-specific meningitis case–fatality data. Pneumococcal and Hib meningitis cases were inferred from modelled pathogen-specific meningitis deaths and literature-derived case–fatality estimates. Cases of pneumococcal and Hib syndromes other than pneumonia and meningitis were estimated using the ratio of pathogen-specific non-pneumonia, non-meningitis cases to pathogen-specific meningitis cases from the literature. We accounted for annual HIV infection prevalence, access to care, and vaccine use. Findings: We estimated that there were 294 000 pneumococcal deaths (uncertainty range [UR] 192 000–366 000) and 29 500 Hib deaths (18 400–40 700) in HIV-uninfected children aged 1–59 months in 2015. An additional 23 300 deaths (15 300–28 700) associated with pneumococcus and fewer than 1000 deaths associated Hib were estimated to have occurred in children infected with HIV. We estimate that pneumococcal deaths declined by 51% (7–74) and Hib deaths by 90% (78–96) from 2000 to 2015. Most children who died of pneumococcus (81%) and Hib (76%) presented with pneumonia. Less conservative assumptions result in pneumococcccal death estimates that could be as high as 515 000 deaths (302 000–609 000) in 2015. Approximately 50% of all pneumococcal deaths in 2015 occurred in four countries in Africa and Asia: India (68 700 deaths, UR 44 600–86 100), Nigeria (49 000 deaths, 32 400–59 000), the Democratic Republic of the Congo (14 500 deaths, 9300–18 700), and Pakistan (14 400 deaths, 9700–17 000]). India (15 600 deaths, 9800–21 500), Nigeria (3600 deaths, 2200–5100), China (3400 deaths, 2300–4600), and South Sudan (1000 deaths, 600–1400) had the greatest number of Hib deaths in 2015. We estimated 3·7 million episodes (UR 2·7 million–4·3 million) of severe pneumococcus and 340 000 episodes (196 000–669 000) of severe Hib globally in children in 2015. Interpretation: The widespread use of Hib vaccine and the recent introduction of PCV in countries with high child mortality is associated with reductions in Hib and pneumococcal cases and deaths. Uncertainties in the burden of pneumococcal disease are largely driven by the fraction of pneumonia deaths attributable to pneumococcus. Progress towards further reducing the global burden of Hib and pneumococcal disease burden will depend on the efforts of a few large countries in Africa and Asia. Funding: Bill & Melinda Gates Foundation.
Pneumococcal conjugate vaccine (PCV) and Haemophilus influenzae type b (Hib) vaccine are now used in most countries. To monitor global and regional progress towards improving child health and to inform national policies for disease prevention and treatment, we prepared global, regional, and national disease burden estimates for these pathogens in children from 2000 to 2015.BACKGROUNDPneumococcal conjugate vaccine (PCV) and Haemophilus influenzae type b (Hib) vaccine are now used in most countries. To monitor global and regional progress towards improving child health and to inform national policies for disease prevention and treatment, we prepared global, regional, and national disease burden estimates for these pathogens in children from 2000 to 2015.Using WHO and Maternal and Child Epidemiology Estimation collaboration country-specific estimates of pneumonia and meningitis mortality and pneumonia morbidity from 2000 to 2015, we applied pneumococcal and Hib cause-specific proportions to estimate pathogen-specific deaths and cases. Summary estimates of the proportion of pneumonia deaths and cases attributable to these pathogens were derived from four Hib vaccine and six PCV efficacy and effectiveness study values. The proportion of meningitis deaths due to each pathogen was derived from bacterial meningitis aetiology and adjusted pathogen-specific meningitis case-fatality data. Pneumococcal and Hib meningitis cases were inferred from modelled pathogen-specific meningitis deaths and literature-derived case-fatality estimates. Cases of pneumococcal and Hib syndromes other than pneumonia and meningitis were estimated using the ratio of pathogen-specific non-pneumonia, non-meningitis cases to pathogen-specific meningitis cases from the literature. We accounted for annual HIV infection prevalence, access to care, and vaccine use.METHODSUsing WHO and Maternal and Child Epidemiology Estimation collaboration country-specific estimates of pneumonia and meningitis mortality and pneumonia morbidity from 2000 to 2015, we applied pneumococcal and Hib cause-specific proportions to estimate pathogen-specific deaths and cases. Summary estimates of the proportion of pneumonia deaths and cases attributable to these pathogens were derived from four Hib vaccine and six PCV efficacy and effectiveness study values. The proportion of meningitis deaths due to each pathogen was derived from bacterial meningitis aetiology and adjusted pathogen-specific meningitis case-fatality data. Pneumococcal and Hib meningitis cases were inferred from modelled pathogen-specific meningitis deaths and literature-derived case-fatality estimates. Cases of pneumococcal and Hib syndromes other than pneumonia and meningitis were estimated using the ratio of pathogen-specific non-pneumonia, non-meningitis cases to pathogen-specific meningitis cases from the literature. We accounted for annual HIV infection prevalence, access to care, and vaccine use.We estimated that there were 294 000 pneumococcal deaths (uncertainty range [UR] 192 000-366 000) and 29 500 Hib deaths (18 400-40 700) in HIV-uninfected children aged 1-59 months in 2015. An additional 23 300 deaths (15 300-28 700) associated with pneumococcus and fewer than 1000 deaths associated Hib were estimated to have occurred in children infected with HIV. We estimate that pneumococcal deaths declined by 51% (7-74) and Hib deaths by 90% (78-96) from 2000 to 2015. Most children who died of pneumococcus (81%) and Hib (76%) presented with pneumonia. Less conservative assumptions result in pneumococcccal death estimates that could be as high as 515 000 deaths (302 000-609 000) in 2015. Approximately 50% of all pneumococcal deaths in 2015 occurred in four countries in Africa and Asia: India (68 700 deaths, UR 44 600-86 100), Nigeria (49 000 deaths, 32 400-59 000), the Democratic Republic of the Congo (14 500 deaths, 9300-18 700), and Pakistan (14 400 deaths, 9700-17 000]). India (15 600 deaths, 9800-21 500), Nigeria (3600 deaths, 2200-5100), China (3400 deaths, 2300-4600), and South Sudan (1000 deaths, 600-1400) had the greatest number of Hib deaths in 2015. We estimated 3·7 million episodes (UR 2·7 million-4·3 million) of severe pneumococcus and 340 000 episodes (196 000-669 000) of severe Hib globally in children in 2015.FINDINGSWe estimated that there were 294 000 pneumococcal deaths (uncertainty range [UR] 192 000-366 000) and 29 500 Hib deaths (18 400-40 700) in HIV-uninfected children aged 1-59 months in 2015. An additional 23 300 deaths (15 300-28 700) associated with pneumococcus and fewer than 1000 deaths associated Hib were estimated to have occurred in children infected with HIV. We estimate that pneumococcal deaths declined by 51% (7-74) and Hib deaths by 90% (78-96) from 2000 to 2015. Most children who died of pneumococcus (81%) and Hib (76%) presented with pneumonia. Less conservative assumptions result in pneumococcccal death estimates that could be as high as 515 000 deaths (302 000-609 000) in 2015. Approximately 50% of all pneumococcal deaths in 2015 occurred in four countries in Africa and Asia: India (68 700 deaths, UR 44 600-86 100), Nigeria (49 000 deaths, 32 400-59 000), the Democratic Republic of the Congo (14 500 deaths, 9300-18 700), and Pakistan (14 400 deaths, 9700-17 000]). India (15 600 deaths, 9800-21 500), Nigeria (3600 deaths, 2200-5100), China (3400 deaths, 2300-4600), and South Sudan (1000 deaths, 600-1400) had the greatest number of Hib deaths in 2015. We estimated 3·7 million episodes (UR 2·7 million-4·3 million) of severe pneumococcus and 340 000 episodes (196 000-669 000) of severe Hib globally in children in 2015.The widespread use of Hib vaccine and the recent introduction of PCV in countries with high child mortality is associated with reductions in Hib and pneumococcal cases and deaths. Uncertainties in the burden of pneumococcal disease are largely driven by the fraction of pneumonia deaths attributable to pneumococcus. Progress towards further reducing the global burden of Hib and pneumococcal disease burden will depend on the efforts of a few large countries in Africa and Asia.INTERPRETATIONThe widespread use of Hib vaccine and the recent introduction of PCV in countries with high child mortality is associated with reductions in Hib and pneumococcal cases and deaths. Uncertainties in the burden of pneumococcal disease are largely driven by the fraction of pneumonia deaths attributable to pneumococcus. Progress towards further reducing the global burden of Hib and pneumococcal disease burden will depend on the efforts of a few large countries in Africa and Asia.Bill & Melinda Gates Foundation.FUNDINGBill & Melinda Gates Foundation.
Author Black, Robert
Liu, Li
Rudan, Igor
Campbell, Harry
O'Brien, Katherine L
Greenbaum, Adena
Nair, Harish
Knoll, Maria Deloria
Lukšić, Ivana
McAllister, David A
Wahl, Brian
Majumder, Anwesha
Chu, Yue
AuthorAffiliation b Institute for International Programs, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
f Public Health Foundation of India, New Delhi, India
e Usher Institute of Population Health Sciences and Informatics, Medical School, University of Edinburgh, Edinburgh, UK
d Department of Microbiology, Dr Andrija Štampar Institute of Public Health, Zagreb, Croatia
g Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK
a International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
c Department of International Health and Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
AuthorAffiliation_xml – name: g Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK
– name: f Public Health Foundation of India, New Delhi, India
– name: a International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
– name: b Institute for International Programs, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
– name: e Usher Institute of Population Health Sciences and Informatics, Medical School, University of Edinburgh, Edinburgh, UK
– name: c Department of International Health and Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
– name: d Department of Microbiology, Dr Andrija Štampar Institute of Public Health, Zagreb, Croatia
Author_xml – sequence: 1
  givenname: Brian
  surname: Wahl
  fullname: Wahl, Brian
  email: bwahl@jhu.edu
  organization: International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
– sequence: 2
  givenname: Katherine L
  surname: O'Brien
  fullname: O'Brien, Katherine L
  organization: International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
– sequence: 3
  givenname: Adena
  surname: Greenbaum
  fullname: Greenbaum, Adena
  organization: International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
– sequence: 4
  givenname: Anwesha
  surname: Majumder
  fullname: Majumder, Anwesha
  organization: International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
– sequence: 5
  givenname: Li
  surname: Liu
  fullname: Liu, Li
  organization: Institute for International Programs, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
– sequence: 6
  givenname: Yue
  surname: Chu
  fullname: Chu, Yue
  organization: Institute for International Programs, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
– sequence: 7
  givenname: Ivana
  surname: Lukšić
  fullname: Lukšić, Ivana
  organization: Department of Microbiology, Dr Andrija Štampar Institute of Public Health, Zagreb, Croatia
– sequence: 8
  givenname: Harish
  surname: Nair
  fullname: Nair, Harish
  organization: Usher Institute of Population Health Sciences and Informatics, Medical School, University of Edinburgh, Edinburgh, UK
– sequence: 9
  givenname: David A
  surname: McAllister
  fullname: McAllister, David A
  organization: Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK
– sequence: 10
  givenname: Harry
  surname: Campbell
  fullname: Campbell, Harry
  organization: Usher Institute of Population Health Sciences and Informatics, Medical School, University of Edinburgh, Edinburgh, UK
– sequence: 11
  givenname: Igor
  surname: Rudan
  fullname: Rudan, Igor
  organization: Usher Institute of Population Health Sciences and Informatics, Medical School, University of Edinburgh, Edinburgh, UK
– sequence: 12
  givenname: Robert
  surname: Black
  fullname: Black, Robert
  organization: Institute for International Programs, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
– sequence: 13
  givenname: Maria Deloria
  surname: Knoll
  fullname: Knoll, Maria Deloria
  organization: International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29903376$$D View this record in MEDLINE/PubMed
BookMark eNqNks9u1DAQxiNUREvpI4B8LBILtuP8MRUgqIBWqsShIO3NciaTXS9eO9jJSuXEO_AkvBJPgne3rdpeig_xxDPf77PG8zjbcd5hlj1l9CWjrHx1zjkTE0bl9JDVz3PKRTWZPsj2ro93bsS72UGMC5qWlDmvqkfZLpeS5nlV7mV_PoyhRUd8R86HgP3gwQOMkfQOx6V3RiPRriUnGpe-nxubUsZ1dkT3M6WGix5JQ1oTUUdMGQKppg2JmOJhjgSDXsPBu8U40wOSlQYwDuNrMrO-0fYFCTgz3q2jtZPTw-aPYBzMMiki6XwgPN3_76_frHiSPey0jXhwue9n3z59_Hp8Mjn78vn0-P3ZBMoiHyai5JCLQredaDBHVrd5UdeYs6IUUnTpS5E2Emkn864qQVS5BF5KKkvW6tSp_ex0y229Xqg-pLuEC-W1UZsDH2ZKh8GARQVactF0suSdFoyC5DXUXEDHeC1E0STW2y2rH5sltoBuCNregt7OODNXM79SJaUF4zwBDi8Bwf8YU2fU0kRAa7VDP0bFaVHmMplVqfTZTa9rk6s3TwVH2wIIPsaAnQIzbJqerI1VjKr1kKnNkKn1BClWq82QqWlSF3fUVwb36d5tdZjebGUwqAgGHWBrAsKQmmruJby5QwBrnAFtv-PFf-j_AY_qADM
CitedBy_id crossref_primary_10_1093_ofid_ofaf050
crossref_primary_10_3389_fcimb_2022_949469
crossref_primary_10_3389_fcimb_2025_1635180
crossref_primary_10_7774_cevr_2025_14_e19
crossref_primary_10_1016_j_lanwpc_2021_100231
crossref_primary_10_1016_j_vaccine_2019_10_011
crossref_primary_10_1016_j_meegid_2021_104984
crossref_primary_10_1016_S1473_3099_18_30785_0
crossref_primary_10_1016_S1473_3099_22_00526_6
crossref_primary_10_3389_fpubh_2023_1184059
crossref_primary_10_1186_s40249_023_01142_8
crossref_primary_10_1097_INF_0000000000003091
crossref_primary_10_3389_fbioe_2023_1108300
crossref_primary_10_1186_s40249_023_01165_1
crossref_primary_10_4102_sajid_v36i1_244
crossref_primary_10_1186_s12879_024_10110_y
crossref_primary_10_1371_journal_ppat_1010458
crossref_primary_10_1016_j_vaccine_2021_08_068
crossref_primary_10_2147_IDR_S424468
crossref_primary_10_1007_s40121_021_00523_6
crossref_primary_10_3389_fped_2020_587730
crossref_primary_10_1186_s12866_025_04047_8
crossref_primary_10_3390_vaccines8020187
crossref_primary_10_1097_INF_0000000000004069
crossref_primary_10_1007_s40273_025_01504_0
crossref_primary_10_1128_spectrum_03579_23
crossref_primary_10_3389_fpubh_2024_1337276
crossref_primary_10_1186_s12879_022_07289_3
crossref_primary_10_1016_j_vaccine_2022_09_018
crossref_primary_10_3390_toxins13020157
crossref_primary_10_4102_jphia_v16i1_880
crossref_primary_10_3389_fcimb_2022_866186
crossref_primary_10_1016_j_vaccine_2020_06_067
crossref_primary_10_1080_21645515_2024_2313872
crossref_primary_10_1038_s41467_024_50944_3
crossref_primary_10_1097_INF_0000000000004192
crossref_primary_10_1016_j_jddst_2020_102142
crossref_primary_10_3389_fcimb_2019_00258
crossref_primary_10_1016_j_epidem_2022_100590
crossref_primary_10_1016_S1473_3099_21_00002_5
crossref_primary_10_1128_CMR_00028_21
crossref_primary_10_1371_journal_pone_0315461
crossref_primary_10_1128_AAC_00711_19
crossref_primary_10_1016_S2352_3026_23_00066_2
crossref_primary_10_1001_jamanetworkopen_2022_18959
crossref_primary_10_1073_pnas_1812388116
crossref_primary_10_3390_microorganisms10020469
crossref_primary_10_3390_healthcare13161982
crossref_primary_10_1007_s11356_022_21334_3
crossref_primary_10_1093_cid_ciz457
crossref_primary_10_1093_femsre_fuaa067
crossref_primary_10_1093_cid_ciz456
crossref_primary_10_1016_j_heliyon_2024_e25741
crossref_primary_10_1016_j_vaccine_2019_10_030
crossref_primary_10_1093_infdis_jiz024
crossref_primary_10_1128_spectrum_01294_24
crossref_primary_10_3389_fcimb_2023_1332472
crossref_primary_10_3390_tropicalmed10080236
crossref_primary_10_1016_j_jiph_2019_06_021
crossref_primary_10_1097_INF_0000000000003190
crossref_primary_10_3390_math12060796
crossref_primary_10_1164_rccm_202302_0222OC
crossref_primary_10_1186_s41479_023_00114_8
crossref_primary_10_1021_acsomega_5c01541
crossref_primary_10_1186_s12879_024_09493_9
crossref_primary_10_1016_j_vaccine_2018_08_029
crossref_primary_10_3390_vaccines13080847
crossref_primary_10_12688_wellcomeopenres_17172_2
crossref_primary_10_1371_journal_pone_0316444
crossref_primary_10_1128_spectrum_01524_22
crossref_primary_10_12688_wellcomeopenres_17172_1
crossref_primary_10_1002_ppul_24533
crossref_primary_10_3390_vaccines13080860
crossref_primary_10_1016_j_envres_2022_113156
crossref_primary_10_1016_j_vacune_2020_02_002
crossref_primary_10_1016_j_jhazmat_2025_137321
crossref_primary_10_1007_s13312_024_3178_0
crossref_primary_10_1016_j_jinf_2023_01_012
crossref_primary_10_1128_MRA_00511_19
crossref_primary_10_1080_21645515_2022_2087411
crossref_primary_10_1016_S0140_6736_18_33005_8
crossref_primary_10_3389_fimmu_2022_1005344
crossref_primary_10_1093_cid_ciz464
crossref_primary_10_1016_j_pccm_2025_08_006
crossref_primary_10_1093_cid_ciaa919
crossref_primary_10_1371_journal_pone_0232151
crossref_primary_10_1073_pnas_2010428117
crossref_primary_10_1371_journal_pgen_1011188
crossref_primary_10_1097_IPC_0000000000000821
crossref_primary_10_1038_s41564_022_01208_7
crossref_primary_10_1016_j_jiph_2022_06_016
crossref_primary_10_1016_S1473_3099_20_30880_X
crossref_primary_10_1093_ofid_ofaf093
crossref_primary_10_4103_ijmm_IJMM_19_320
crossref_primary_10_1016_j_vaccine_2022_10_072
crossref_primary_10_1016_j_vaccine_2023_04_008
crossref_primary_10_3389_fpubh_2023_1110903
crossref_primary_10_1016_j_lanwpc_2022_100430
crossref_primary_10_1016_j_lanwpc_2024_101082
crossref_primary_10_7705_biomedica_5407
crossref_primary_10_1016_S1473_3099_21_00672_1
crossref_primary_10_1186_s12879_020_05674_4
crossref_primary_10_1093_infdis_jiab226
crossref_primary_10_3390_vaccines13070707
crossref_primary_10_1016_j_lanwpc_2021_100273
crossref_primary_10_3390_ijms241311150
crossref_primary_10_35366_102965
crossref_primary_10_1093_cid_ciz472
crossref_primary_10_1093_cid_ciz350
crossref_primary_10_3390_vaccines9030209
crossref_primary_10_1371_journal_pone_0284810
crossref_primary_10_1038_s41467_019_08869_9
crossref_primary_10_1038_s41467_023_38277_z
crossref_primary_10_1093_cid_ciz474
crossref_primary_10_1099_mgen_0_001191
crossref_primary_10_1002_ange_202211940
crossref_primary_10_1542_peds_2021_056013
crossref_primary_10_3390_vaccines13040349
crossref_primary_10_1001_jamanetworkopen_2022_25141
crossref_primary_10_1080_14760584_2023_2173176
crossref_primary_10_1186_s41479_024_00141_z
crossref_primary_10_1128_jcm_01079_24
crossref_primary_10_1128_JCM_02103_20
crossref_primary_10_25122_jml_2023_0404
crossref_primary_10_1007_s40121_021_00544_1
crossref_primary_10_1093_infdis_jiab119
crossref_primary_10_7189_jogh_10_010416
crossref_primary_10_1016_j_jped_2019_08_003
crossref_primary_10_1016_j_vaccine_2025_127193
crossref_primary_10_3389_fped_2023_1095166
crossref_primary_10_1007_s10096_020_03991_9
crossref_primary_10_1016_j_jgar_2024_01_013
crossref_primary_10_1111_tmi_13809
crossref_primary_10_1016_j_vaccine_2024_05_031
crossref_primary_10_1016_j_jiph_2025_102797
crossref_primary_10_3389_fcimb_2019_00459
crossref_primary_10_1186_s12941_025_00818_3
crossref_primary_10_1016_j_vacune_2025_500452
crossref_primary_10_1016_S2352_4642_23_00328_0
crossref_primary_10_1186_s12879_022_07179_8
crossref_primary_10_1080_21505594_2024_2387180
crossref_primary_10_1186_s12879_024_10371_7
crossref_primary_10_1016_j_ijid_2023_05_016
crossref_primary_10_1186_s12879_025_11377_5
crossref_primary_10_25122_jml_2024_0044
crossref_primary_10_1016_j_envpol_2024_125604
crossref_primary_10_5812_ijp_106086
crossref_primary_10_1007_s11033_021_06353_6
crossref_primary_10_1016_j_lanwpc_2022_100651
crossref_primary_10_1016_S2468_2667_23_00248_7
crossref_primary_10_1128_spectrum_00497_22
crossref_primary_10_1016_j_ccc_2022_07_001
crossref_primary_10_1016_j_vaccine_2023_05_064
crossref_primary_10_1080_21645515_2025_2460274
crossref_primary_10_1099_mgen_0_001094
crossref_primary_10_1007_s00431_020_03865_4
crossref_primary_10_1371_journal_pone_0317216
crossref_primary_10_3390_vaccines9080921
crossref_primary_10_1128_spectrum_00005_23
crossref_primary_10_1016_j_jiac_2020_11_019
crossref_primary_10_1186_s13073_022_01147_2
crossref_primary_10_1186_s41479_024_00152_w
crossref_primary_10_3390_vaccines9040384
crossref_primary_10_1101_gr_279435_124
crossref_primary_10_1080_14760584_2021_1917391
crossref_primary_10_1097_INF_0000000000003277
crossref_primary_10_1007_s40121_020_00330_5
crossref_primary_10_1016_j_vaccine_2023_04_036
crossref_primary_10_1016_j_vaccine_2024_05_018
crossref_primary_10_1016_j_mucimm_2023_07_004
crossref_primary_10_1007_s10096_025_05094_9
crossref_primary_10_3389_fbrio_2025_1578341
crossref_primary_10_1093_infdis_jiab217
crossref_primary_10_3390_microorganisms9020377
crossref_primary_10_7705_biomedica_5658
crossref_primary_10_4102_sajid_v34i1_112
crossref_primary_10_1007_s40121_021_00434_6
crossref_primary_10_1093_cid_ciz260
crossref_primary_10_5812_apid_160660
crossref_primary_10_1186_s12889_019_6639_y
crossref_primary_10_1016_j_lanwpc_2022_100666
crossref_primary_10_1016_j_vaccine_2021_01_046
crossref_primary_10_1128_spectrum_00138_25
crossref_primary_10_7554_eLife_69244
crossref_primary_10_1371_journal_pone_0240922
crossref_primary_10_3390_idr13010022
crossref_primary_10_1016_j_lana_2023_100448
crossref_primary_10_1128_aac_01395_21
crossref_primary_10_1055_s_0042_1760446
crossref_primary_10_1038_s41598_020_79175_4
crossref_primary_10_1080_14760584_2024_2335323
crossref_primary_10_1097_INF_0000000000004334
crossref_primary_10_1186_s12879_022_07902_5
crossref_primary_10_12688_gatesopenres_13206_1
crossref_primary_10_1038_s41598_020_62846_7
crossref_primary_10_1016_j_vaccine_2019_05_078
crossref_primary_10_3389_fmicb_2020_00309
crossref_primary_10_1099_mgen_0_001264
crossref_primary_10_1016_S1473_3099_20_30735_0
crossref_primary_10_1093_infdis_jiab268
crossref_primary_10_1099_mgen_0_000299
crossref_primary_10_1093_ofid_ofaa444
crossref_primary_10_3390_microorganisms9071365
crossref_primary_10_1080_21645515_2025_2545032
crossref_primary_10_1093_jac_dkaf219
crossref_primary_10_1128_mSphere_00852_20
crossref_primary_10_1016_j_ijid_2019_01_035
crossref_primary_10_1155_2021_4923852
crossref_primary_10_1111_cmi_13077
crossref_primary_10_1186_s12879_023_08611_3
crossref_primary_10_1016_j_ijid_2020_05_078
crossref_primary_10_1016_j_vaccine_2020_08_068
crossref_primary_10_1016_j_envpol_2025_126303
crossref_primary_10_1136_bmjgh_2020_003451
crossref_primary_10_1371_journal_pone_0326992
crossref_primary_10_3390_pathogens9040278
crossref_primary_10_1371_journal_pone_0291203
crossref_primary_10_1016_j_eimce_2023_04_008
crossref_primary_10_1128_aem_01336_24
crossref_primary_10_3390_vaccines8030387
crossref_primary_10_1371_journal_pbio_3003300
crossref_primary_10_1093_infdis_jiab037
crossref_primary_10_1099_mgen_0_001398
crossref_primary_10_1186_s12879_024_10065_0
crossref_primary_10_1186_s43141_023_00506_9
crossref_primary_10_1177_23333928231186687
crossref_primary_10_1093_infdis_jiz408
crossref_primary_10_3389_fmolb_2022_961532
crossref_primary_10_1073_pnas_2004933118
crossref_primary_10_1099_mgen_0_001163
crossref_primary_10_1016_j_vaccine_2021_09_029
crossref_primary_10_1371_journal_pcbi_1009389
crossref_primary_10_1016_j_ijid_2025_108042
crossref_primary_10_1001_jama_2025_0865
crossref_primary_10_1128_iai_00100_23
crossref_primary_10_1080_14760584_2023_2296934
crossref_primary_10_1080_14656566_2022_2028773
crossref_primary_10_1038_s42003_020_01290_9
crossref_primary_10_3390_vaccines10081368
crossref_primary_10_1001_jamapediatrics_2018_3846
crossref_primary_10_1016_j_vaccine_2021_06_043
crossref_primary_10_1007_s40121_024_00977_4
crossref_primary_10_1097_INF_0000000000003223
crossref_primary_10_1097_INF_0000000000004318
crossref_primary_10_1016_j_jinf_2022_05_040
crossref_primary_10_3390_antibiotics10050573
crossref_primary_10_1016_j_lanwpc_2020_100018
crossref_primary_10_1186_s41479_021_00085_8
crossref_primary_10_1016_j_vaccine_2020_12_066
crossref_primary_10_3345_cep_2019_01067
crossref_primary_10_1080_21645515_2024_2417554
crossref_primary_10_1016_j_ijid_2024_107268
crossref_primary_10_1186_s12889_021_12108_6
crossref_primary_10_1016_j_cmi_2020_05_029
crossref_primary_10_1016_j_vaccine_2025_127138
crossref_primary_10_1016_j_prrv_2020_09_005
crossref_primary_10_1080_17843286_2022_2039865
crossref_primary_10_1016_j_vaccine_2019_12_038
crossref_primary_10_1038_s41467_024_51413_7
crossref_primary_10_1111_resp_14389
crossref_primary_10_3201_eid2701_201178
crossref_primary_10_1016_j_ebiom_2021_103579
crossref_primary_10_1016_S0140_6736_21_00883_7
crossref_primary_10_53933_sspmpm_v2i4_69
crossref_primary_10_1080_14737167_2021_1855978
crossref_primary_10_1080_14760584_2021_1965474
crossref_primary_10_1007_s40121_023_00878_y
crossref_primary_10_1371_journal_pone_0248722
crossref_primary_10_1002_pep2_24222
crossref_primary_10_1111_irv_12881
crossref_primary_10_1056_NEJMoa2400007
crossref_primary_10_1016_j_jbc_2023_105085
crossref_primary_10_1016_j_vaccine_2022_09_062
crossref_primary_10_1016_j_ccm_2023_03_015
crossref_primary_10_1016_j_ijid_2021_11_021
crossref_primary_10_1542_pir_2020_0062
crossref_primary_10_33073_pjm_2023_023
crossref_primary_10_1016_S1473_3099_24_00176_2
crossref_primary_10_1371_journal_pone_0253239
crossref_primary_10_1016_j_vaccine_2019_12_060
crossref_primary_10_7554_eLife_46202
crossref_primary_10_1007_s00431_025_06137_1
crossref_primary_10_1016_S1473_3099_19_30297_X
crossref_primary_10_3389_fped_2022_1006887
crossref_primary_10_1093_infdis_jiab069
crossref_primary_10_1016_j_vaccine_2021_07_055
crossref_primary_10_1016_S1473_3099_23_00572_8
crossref_primary_10_3389_fmicb_2021_793050
crossref_primary_10_3390_vaccines7010018
crossref_primary_10_1093_infdis_jiac154
crossref_primary_10_1111_jam_15090
crossref_primary_10_12688_f1000research_15758_1
crossref_primary_10_35366_118345
crossref_primary_10_1136_bmjgh_2020_002669
crossref_primary_10_7759_cureus_80170
crossref_primary_10_2147_IJGM_S409476
crossref_primary_10_1136_bmjopen_2019_034663
crossref_primary_10_1097_WCO_0000000000000934
crossref_primary_10_7189_jogh_11_04054
crossref_primary_10_1038_s41467_020_15786_9
crossref_primary_10_1097_INF_0000000000004300
crossref_primary_10_3389_fmicb_2022_798853
crossref_primary_10_3201_eid2809_220313
crossref_primary_10_3389_fimmu_2022_1020580
crossref_primary_10_1038_s41598_022_06950_w
crossref_primary_10_12688_f1000research_22341_1
crossref_primary_10_4155_bio_2020_0024
crossref_primary_10_1093_cid_ciaa1483
crossref_primary_10_1186_s41479_025_00162_2
crossref_primary_10_2147_PHMT_S467351
crossref_primary_10_1016_j_sjbs_2021_08_054
crossref_primary_10_1093_infdis_jiab072
crossref_primary_10_1371_journal_pone_0231041
crossref_primary_10_1016_j_mtcomm_2022_103894
crossref_primary_10_1038_s41541_025_01187_w
crossref_primary_10_1093_infdis_jiab073
crossref_primary_10_1016_j_ijbiomac_2025_144311
crossref_primary_10_1093_nar_gkae1140
crossref_primary_10_3390_vaccines11121750
crossref_primary_10_1080_22221751_2025_2532685
crossref_primary_10_3389_fonc_2020_00548
crossref_primary_10_1097_INF_0000000000003421
crossref_primary_10_1371_journal_pone_0246522
crossref_primary_10_3389_fimmu_2025_1550227
crossref_primary_10_1016_j_puhe_2025_105820
crossref_primary_10_1093_cid_ciad562
crossref_primary_10_1128_cmr_00175_24
crossref_primary_10_3389_fped_2023_1198278
crossref_primary_10_1016_j_cmi_2020_04_033
crossref_primary_10_1093_cid_ciac475
crossref_primary_10_3201_eid3102_241652
crossref_primary_10_1371_journal_pone_0277348
crossref_primary_10_1099_mgen_0_000274
crossref_primary_10_1016_j_vaccine_2023_03_063
crossref_primary_10_1038_s41467_020_17327_w
crossref_primary_10_1007_s40121_021_00498_4
crossref_primary_10_1371_journal_pone_0211784
crossref_primary_10_1099_mgen_0_001123
crossref_primary_10_1093_infdis_jiac376
crossref_primary_10_1080_22221751_2022_2040921
crossref_primary_10_1111_irv_13303
crossref_primary_10_3390_vaccines11081369
crossref_primary_10_1016_S1473_3099_22_00760_5
crossref_primary_10_1096_fj_201902988RR
crossref_primary_10_7554_eLife_67113
crossref_primary_10_1016_S1474_4422_23_00195_3
crossref_primary_10_1016_j_arbr_2020_09_002
crossref_primary_10_1186_s12879_020_4810_9
crossref_primary_10_3389_fimmu_2022_992659
crossref_primary_10_3389_fcimb_2024_1467320
crossref_primary_10_1016_j_vaccine_2021_08_049
crossref_primary_10_1097_INF_0000000000004638
crossref_primary_10_1371_journal_pone_0297041
crossref_primary_10_2147_IDR_S256663
crossref_primary_10_1016_j_jvacx_2025_100688
crossref_primary_10_15789_2220_7619_TEP_17794
crossref_primary_10_1002_1873_3468_13758
crossref_primary_10_1186_s12879_021_06570_1
crossref_primary_10_1016_S2352_4642_23_00055_X
crossref_primary_10_1097_INF_0000000000003554
crossref_primary_10_1371_journal_pone_0328516
crossref_primary_10_3389_fimmu_2021_638917
crossref_primary_10_1016_S0992_5945_22_00235_5
crossref_primary_10_1007_s12664_020_01069_0
crossref_primary_10_1038_s41541_022_00538_1
crossref_primary_10_1097_INF_0000000000002581
crossref_primary_10_1136_bmjgh_2021_007080
crossref_primary_10_1371_journal_pone_0305892
crossref_primary_10_1016_j_tim_2021_11_007
crossref_primary_10_3389_fpubh_2023_1244357
crossref_primary_10_1016_S2352_4642_20_30129_2
crossref_primary_10_1016_S1473_3099_20_30492_8
crossref_primary_10_1016_j_vaccine_2020_06_047
crossref_primary_10_1099_mgen_0_001262
crossref_primary_10_1093_infdis_jiab172
crossref_primary_10_1016_j_vaccine_2023_02_041
crossref_primary_10_1097_INF_0000000000004528
crossref_primary_10_1080_14760584_2021_1894933
crossref_primary_10_1016_j_tim_2022_06_001
crossref_primary_10_1136_bmjgh_2021_005187
crossref_primary_10_1016_j_vaccine_2025_127669
crossref_primary_10_1016_j_diagmicrobio_2025_116870
crossref_primary_10_1016_j_ijid_2019_06_024
crossref_primary_10_12688_gatesopenres_13576_1
crossref_primary_10_3389_fimmu_2023_1175275
crossref_primary_10_3390_microorganisms9040696
crossref_primary_10_1002_cbic_202400684
crossref_primary_10_1016_j_jmii_2021_06_006
crossref_primary_10_1007_s40121_025_01108_3
crossref_primary_10_1093_infdis_jiaf106
crossref_primary_10_1177_20499361241274206
crossref_primary_10_1016_j_vaccine_2022_06_059
crossref_primary_10_1016_j_jmii_2022_08_018
crossref_primary_10_1186_s12931_022_02115_5
crossref_primary_10_1016_j_ijid_2018_12_009
crossref_primary_10_1016_j_ijregi_2025_100707
crossref_primary_10_1016_j_vaccine_2019_07_073
crossref_primary_10_1177_20503121231163792
crossref_primary_10_1080_17513758_2021_1884760
crossref_primary_10_1183_13993003_02432_2021
crossref_primary_10_1099_mgen_0_001433
crossref_primary_10_3389_fcimb_2021_744727
crossref_primary_10_3390_vaccines12040393
crossref_primary_10_1038_s41586_020_2238_4
crossref_primary_10_1016_S1473_3099_18_30407_9
crossref_primary_10_1080_21645515_2022_2090162
crossref_primary_10_1093_infdis_jiae144
crossref_primary_10_1093_jac_dkaa276
crossref_primary_10_1186_s12879_019_4254_2
crossref_primary_10_1016_j_lana_2025_101113
crossref_primary_10_1093_cid_ciae619
crossref_primary_10_1186_s41479_023_00109_5
crossref_primary_10_1080_16549716_2023_2281065
crossref_primary_10_2147_IJGM_S333751
crossref_primary_10_1093_jacamr_dlab066
crossref_primary_10_3390_vaccines13060644
crossref_primary_10_1016_j_vaccine_2025_127762
crossref_primary_10_3390_arm91020012
crossref_primary_10_1080_14760584_2021_1971521
crossref_primary_10_1080_21645515_2022_2114252
crossref_primary_10_1002_bab_2514
crossref_primary_10_1099_mgen_0_001444
crossref_primary_10_1080_23744235_2024_2440033
crossref_primary_10_1007_s13312_020_1701_5
crossref_primary_10_1016_j_vaccine_2021_04_024
crossref_primary_10_1128_spectrum_00913_23
crossref_primary_10_1177_2333794X221108963
crossref_primary_10_1542_peds_2022_060428
crossref_primary_10_1016_j_vaccine_2020_11_044
crossref_primary_10_1093_jpids_piac038
crossref_primary_10_1128_AAC_01974_19
crossref_primary_10_12688_wellcomeopenres_15689_1
crossref_primary_10_1021_acsbiomedchemau_5c00010
crossref_primary_10_3389_fpubh_2024_1402795
crossref_primary_10_12688_wellcomeopenres_15689_2
crossref_primary_10_1016_j_jiph_2024_102600
crossref_primary_10_1371_journal_pone_0256856
crossref_primary_10_1056_NEJMoa1911998
crossref_primary_10_1007_s40121_021_00485_9
crossref_primary_10_3389_fpubh_2024_1298222
crossref_primary_10_1186_s12866_020_02032_x
crossref_primary_10_1007_s40121_025_01162_x
crossref_primary_10_1016_j_vaccine_2024_03_056
crossref_primary_10_1016_j_vaccine_2024_03_055
crossref_primary_10_1016_j_vaccine_2024_01_104
crossref_primary_10_3389_fimmu_2020_02120
crossref_primary_10_1016_j_vaccine_2021_04_037
crossref_primary_10_1016_j_eimce_2020_03_008
crossref_primary_10_1016_j_vaccine_2022_06_041
crossref_primary_10_1371_journal_pcbi_1009680
crossref_primary_10_1097_INF_0000000000002549
crossref_primary_10_1016_j_vaccine_2020_10_005
crossref_primary_10_1093_cid_ciad746
crossref_primary_10_1542_peds_2025_071260
crossref_primary_10_1186_s41479_024_00149_5
crossref_primary_10_3201_eid2611_200087
crossref_primary_10_1111_ppe_70064
crossref_primary_10_1016_j_vaccine_2024_126370
crossref_primary_10_1007_s40121_021_00472_0
crossref_primary_10_1007_s40272_023_00584_9
crossref_primary_10_1016_j_ajcnut_2023_02_025
crossref_primary_10_5415_apallergy_0000000000000114
crossref_primary_10_1016_S1473_3099_20_30165_1
crossref_primary_10_1016_j_vaccine_2020_03_033
crossref_primary_10_1016_j_vaccine_2024_01_030
crossref_primary_10_1080_14760584_2023_2294153
crossref_primary_10_1016_j_vaccine_2021_05_041
crossref_primary_10_1016_S1473_3099_20_30775_1
crossref_primary_10_1136_bmjresp_2019_000414
crossref_primary_10_1038_s41541_020_00225_z
crossref_primary_10_3389_fncel_2021_680858
crossref_primary_10_1093_ofid_ofad229
crossref_primary_10_1080_14760584_2021_1994858
crossref_primary_10_1016_j_vaccine_2021_11_032
crossref_primary_10_1371_journal_pone_0250010
crossref_primary_10_1089_mdr_2018_0115
crossref_primary_10_1371_journal_pone_0262466
crossref_primary_10_1007_s40121_025_01151_0
crossref_primary_10_1038_s41598_022_17600_6
crossref_primary_10_1097_INF_0000000000003606
crossref_primary_10_1136_bmjgh_2021_007211
crossref_primary_10_1016_j_jfma_2020_04_007
crossref_primary_10_1016_j_micpath_2019_103761
crossref_primary_10_1097_INF_0000000000002521
crossref_primary_10_1016_j_vaccine_2020_10_060
crossref_primary_10_1097_INF_0000000000002765
crossref_primary_10_1016_S1473_3099_18_30734_5
crossref_primary_10_1007_s00253_024_13098_2
crossref_primary_10_1186_s12879_020_04998_5
crossref_primary_10_3389_fpubh_2022_967693
crossref_primary_10_3389_fped_2023_1054335
crossref_primary_10_1002_lary_31353
crossref_primary_10_3389_fped_2019_00233
crossref_primary_10_1038_s42003_024_06845_8
crossref_primary_10_1111_febs_15514
crossref_primary_10_1371_journal_pmed_1003733
crossref_primary_10_1186_s12879_024_09028_2
crossref_primary_10_1007_s00247_021_04992_2
crossref_primary_10_3390_nu13010276
crossref_primary_10_1016_j_vaccine_2022_06_024
crossref_primary_10_1186_s41479_019_0064_y
crossref_primary_10_3390_vaccines13060603
crossref_primary_10_1128_iai_00597_21
crossref_primary_10_3389_fpubh_2023_1124016
crossref_primary_10_1016_j_vaccine_2023_09_043
crossref_primary_10_1016_j_vaccine_2025_126995
crossref_primary_10_1093_cid_ciy726
crossref_primary_10_1136_archdischild_2018_316254
crossref_primary_10_1093_jtm_taab063
crossref_primary_10_1016_j_ijmm_2021_151543
crossref_primary_10_1016_j_vaccine_2025_126996
crossref_primary_10_3390_vaccines9060677
crossref_primary_10_1186_s41479_025_00157_z
crossref_primary_10_3389_fpubh_2025_1554694
crossref_primary_10_1093_ofid_ofae303
crossref_primary_10_1016_j_vaccine_2022_07_033
crossref_primary_10_2147_IDR_S544665
crossref_primary_10_12688_wellcomeopenres_19219_1
crossref_primary_10_1016_j_vaccine_2024_01_018
crossref_primary_10_3389_fcimb_2018_00343
crossref_primary_10_3390_pathogens9030159
crossref_primary_10_1371_journal_pgen_1011317
crossref_primary_10_7554_eLife_67635
crossref_primary_10_1080_21645515_2025_2553949
crossref_primary_10_1186_s12916_024_03631_5
crossref_primary_10_3390_vaccines12070767
crossref_primary_10_3201_eid3003_230864
crossref_primary_10_3389_fpubh_2024_1383668
crossref_primary_10_1097_INF_0000000000004913
crossref_primary_10_4081_jphia_2022_2151
crossref_primary_10_1016_j_vaccine_2019_08_073
crossref_primary_10_1186_s12879_024_10379_z
crossref_primary_10_1016_j_vaccine_2019_08_072
crossref_primary_10_1080_21645515_2022_2082205
crossref_primary_10_1038_s41467_023_43160_y
crossref_primary_10_1016_j_jiac_2022_08_006
crossref_primary_10_1080_14760584_2020_1711055
crossref_primary_10_1080_21645515_2023_2180973
crossref_primary_10_1016_j_jiph_2021_01_010
crossref_primary_10_1016_j_vaccine_2021_09_011
crossref_primary_10_1016_j_micpath_2022_105816
crossref_primary_10_3390_children9050657
crossref_primary_10_1016_j_vaccine_2024_126219
crossref_primary_10_12688_gatesopenres_14768_1
crossref_primary_10_1017_dmp_2020_349
crossref_primary_10_1097_INF_0000000000003838
crossref_primary_10_1007_s00431_021_04179_9
crossref_primary_10_1093_ofid_ofab260
crossref_primary_10_1016_j_chom_2020_02_002
crossref_primary_10_7189_jogh_13_04080
crossref_primary_10_1093_cid_ciab645
crossref_primary_10_1016_j_vaccine_2020_08_035
crossref_primary_10_1371_journal_pone_0310274
crossref_primary_10_1016_j_vaccine_2024_126692
crossref_primary_10_1016_j_vaccine_2024_126691
crossref_primary_10_1007_s11136_021_02941_y
crossref_primary_10_1016_j_eimce_2020_10_006
crossref_primary_10_3390_microorganisms9040738
crossref_primary_10_1016_j_jinf_2020_06_064
crossref_primary_10_1128_spectrum_00591_24
crossref_primary_10_1371_journal_pone_0206728
crossref_primary_10_1099_mgen_0_000851
crossref_primary_10_3389_fmicb_2020_593356
crossref_primary_10_26815_acn_2020_00178
crossref_primary_10_1542_peds_2023_065218
crossref_primary_10_3390_vaccines9111338
crossref_primary_10_1016_j_vaccine_2024_126209
crossref_primary_10_1016_j_chembiol_2023_11_003
crossref_primary_10_1016_j_vaccine_2022_03_004
crossref_primary_10_1016_j_arbres_2020_03_025
crossref_primary_10_1016_j_vaccine_2021_02_030
crossref_primary_10_1016_j_ebiom_2025_105781
crossref_primary_10_1016_j_jinf_2020_06_079
crossref_primary_10_3389_fmed_2024_1380125
crossref_primary_10_1099_mgen_0_000622
crossref_primary_10_1371_journal_pone_0302400
crossref_primary_10_1080_14760584_2024_2443223
crossref_primary_10_1097_MD_0000000000030363
crossref_primary_10_1016_j_copbio_2021_01_012
crossref_primary_10_1016_j_vaccine_2022_12_054
crossref_primary_10_3389_fmicb_2024_1423995
crossref_primary_10_1016_j_vaccine_2024_07_025
crossref_primary_10_3390_ijerph18157841
crossref_primary_10_3390_microorganisms9040742
crossref_primary_10_1016_j_vaccine_2024_07_021
crossref_primary_10_1186_s12879_019_3833_6
crossref_primary_10_2196_50678
crossref_primary_10_1111_ped_14853
crossref_primary_10_1371_journal_pone_0224392
crossref_primary_10_1093_aje_kwz191
crossref_primary_10_1093_pch_pxaa066
crossref_primary_10_1136_archdischild_2020_318913
crossref_primary_10_1016_j_jmii_2021_08_002
crossref_primary_10_1128_spectrum_00012_23
crossref_primary_10_1038_s41467_023_36624_8
crossref_primary_10_3389_fpubh_2024_1344089
crossref_primary_10_1016_j_jped_2022_11_003
crossref_primary_10_3390_microorganisms8121987
crossref_primary_10_1186_s12887_018_1374_6
crossref_primary_10_1099_mgen_0_000636
crossref_primary_10_1099_mgen_0_000635
crossref_primary_10_1093_ofid_ofae220
crossref_primary_10_1016_j_vaccine_2019_09_069
crossref_primary_10_1016_j_jval_2022_10_006
crossref_primary_10_1371_journal_ppat_1011493
crossref_primary_10_1016_j_compbiolchem_2021_107492
crossref_primary_10_3390_antibiotics12101546
crossref_primary_10_3390_microorganisms9050886
crossref_primary_10_1080_20477724_2020_1719325
crossref_primary_10_12688_f1000research_132781_1
crossref_primary_10_1007_s40121_022_00699_5
crossref_primary_10_1016_j_vaccine_2022_03_022
crossref_primary_10_12688_f1000research_132781_2
crossref_primary_10_3390_vaccines9121390
crossref_primary_10_1038_s41564_022_01238_1
crossref_primary_10_1016_S1473_3099_24_00719_9
crossref_primary_10_1186_s12941_021_00432_z
crossref_primary_10_1016_j_meegid_2022_105290
crossref_primary_10_1186_s12866_022_02442_z
crossref_primary_10_1099_mgen_0_000645
crossref_primary_10_1093_jpids_piaa132
crossref_primary_10_3390_microorganisms10102054
crossref_primary_10_1371_journal_pone_0214583
crossref_primary_10_1016_j_lanwpc_2023_100764
crossref_primary_10_1186_s12879_025_10672_5
crossref_primary_10_1007_s00018_024_05232_0
crossref_primary_10_1016_j_vaccine_2019_09_079
crossref_primary_10_2147_IDR_S309876
crossref_primary_10_1080_14760584_2020_1843435
crossref_primary_10_2217_fmb_2021_0004
crossref_primary_10_1155_2024_8368996
crossref_primary_10_1093_cid_ciaa1860
crossref_primary_10_1186_s12920_019_0572_x
crossref_primary_10_1038_s41541_025_01125_w
crossref_primary_10_1016_j_vaccine_2019_09_076
crossref_primary_10_1016_j_vaccine_2024_01_068
crossref_primary_10_1097_PEC_0000000000002651
crossref_primary_10_1038_s41586_024_07626_3
crossref_primary_10_1002_anie_202211940
crossref_primary_10_1038_s41598_022_11279_5
crossref_primary_10_1111_nyas_14127
crossref_primary_10_1097_MD_0000000000028479
crossref_primary_10_33393_dti_2020_2103
crossref_primary_10_3389_fpubh_2023_1272562
crossref_primary_10_1016_S1473_3099_24_00740_0
crossref_primary_10_3389_fpubh_2025_1544359
crossref_primary_10_1093_cid_ciz517
crossref_primary_10_1128_MRA_00715_21
crossref_primary_10_1016_S1473_3099_25_00212_9
crossref_primary_10_1016_j_pep_2021_106011
crossref_primary_10_1016_j_jinf_2025_106426
crossref_primary_10_1038_s41598_021_03127_9
crossref_primary_10_3389_fped_2022_945767
crossref_primary_10_1007_s40265_022_01733_z
crossref_primary_10_3389_fpubh_2022_1028525
crossref_primary_10_1016_j_jiph_2023_10_047
crossref_primary_10_1016_j_ijregi_2023_05_005
crossref_primary_10_1016_S1473_3099_22_00438_8
crossref_primary_10_1186_s12916_021_01998_3
crossref_primary_10_1016_j_jgar_2024_08_006
crossref_primary_10_1016_j_vaccine_2023_12_007
crossref_primary_10_1016_S1473_3099_24_00665_0
crossref_primary_10_1016_j_job_2024_06_001
crossref_primary_10_1371_journal_pbio_3000878
crossref_primary_10_1128_jcm_00741_23
crossref_primary_10_1001_jamanetworkopen_2019_13650
crossref_primary_10_4103_1995_7645_370150
crossref_primary_10_1097_ICO_0000000000002884
crossref_primary_10_3345_cep_2019_01739
crossref_primary_10_1186_s12916_021_02049_7
crossref_primary_10_1128_aac_01083_22
crossref_primary_10_1007_s40121_021_00538_z
crossref_primary_10_1016_j_jhazmat_2023_132215
crossref_primary_10_1128_mmbr_00259_24
crossref_primary_10_1007_s10096_021_04238_x
crossref_primary_10_1016_j_eimce_2020_11_014
crossref_primary_10_1016_S1473_3099_18_30568_1
crossref_primary_10_3389_fped_2022_910026
crossref_primary_10_1016_j_micpath_2023_106263
crossref_primary_10_3389_fcimb_2021_648040
crossref_primary_10_1016_j_ijbiomac_2019_12_022
crossref_primary_10_33393_dti_2022_2532
crossref_primary_10_1093_cid_ciaa614
crossref_primary_10_1093_cid_ciaa856
crossref_primary_10_1099_mgen_0_000831
crossref_primary_10_1038_s41467_025_60552_4
crossref_primary_10_1016_S0140_6736_22_02185_7
crossref_primary_10_1099_mgen_0_000837
crossref_primary_10_1016_j_jmii_2023_10_008
crossref_primary_10_1080_14760584_2020_1738226
crossref_primary_10_1128_cmr_00008_21
crossref_primary_10_1186_s13073_021_00901_2
crossref_primary_10_1016_j_vaccine_2022_05_066
crossref_primary_10_1016_j_ijregi_2023_11_014
crossref_primary_10_1128_spectrum_02443_24
crossref_primary_10_1055_a_2588_6965
crossref_primary_10_1186_s13073_023_01200_8
crossref_primary_10_3390_vaccines13080807
crossref_primary_10_1080_21645515_2022_2046433
crossref_primary_10_1016_j_vaccine_2021_03_028
crossref_primary_10_2147_IDR_S519795
crossref_primary_10_1186_s12879_021_06302_5
crossref_primary_10_1016_j_vacun_2025_500452
crossref_primary_10_1371_journal_pone_0240655
crossref_primary_10_1080_14760584_2020_1825948
crossref_primary_10_1080_14760584_2021_1889374
crossref_primary_10_1016_S1474_4422_23_00244_2
crossref_primary_10_7189_jogh_12_10007
crossref_primary_10_1107_S2053230X19009038
crossref_primary_10_1016_S1473_3099_20_30489_8
crossref_primary_10_1128_IAI_00713_20
crossref_primary_10_7189_jogh_12_10004
crossref_primary_10_1038_s41396_021_01108_4
crossref_primary_10_1080_14760584_2024_2411425
crossref_primary_10_7189_jogh_12_10010
crossref_primary_10_1371_journal_pbio_3001990
crossref_primary_10_1186_s12916_020_01601_1
crossref_primary_10_1186_s12866_020_02052_7
crossref_primary_10_1007_s00430_025_00848_w
crossref_primary_10_1016_S1473_3099_22_00734_4
crossref_primary_10_3389_fmicb_2023_1244366
crossref_primary_10_1186_s43168_025_00428_9
crossref_primary_10_1111_tmi_13755
crossref_primary_10_1016_j_eimce_2024_02_011
Cites_doi 10.1056/NEJMoa035060
10.1016/S0140-6736(05)66788-8
10.1097/QAD.0b013e328341b7f1
10.1016/S0140-6736(09)61203-4
10.1371/journal.pmed.1001517
10.1001/jama.1993.03500020080036
10.1016/S0140-6736(16)31593-8
10.1016/S0140-6736(03)14411-X
10.1056/NEJMoa1401914
10.1371/journal.pmed.1001657
10.1016/S0140-6736(96)09267-7
10.1371/journal.pmed.1000348
10.1097/00006454-200209000-00005
10.1016/S0140-6736(13)60222-6
10.1016/S0140-6736(09)61204-6
10.1016/S1473-3099(15)70044-7
10.3201/eid1007.030737
10.1016/S0140-6736(15)00120-8
10.1016/S1473-3099(10)70055-4
10.1016/S2214-109X(15)00316-2
10.1097/INF.0b013e31806166a0
10.1016/S0140-6736(05)71876-6
10.1086/648593
10.1056/NEJMoa1408544
10.2471/BLT.11.087700
10.1016/S0140-6736(04)17664-2
10.1097/00006454-199603000-00008
10.1093/ije/30.3.509
10.1016/S0140-6736(12)61901-1
10.1086/429828
10.1097/00006454-200003000-00003
10.1097/01.inf.0000232706.35674.2f
10.1097/00006454-199912000-00006
10.1097/INF.0b013e31819637af
10.1016/S1473-3099(17)30396-1
10.1093/cid/civ059
10.2471/BLT.05.027003
10.1016/S0140-6736(11)60888-X
10.1371/journal.pmed.1002056
ContentType Journal Article
Copyright 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2018
Copyright_xml – notice: 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
– notice: Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
– notice: 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2018
DBID 6I.
AAFTH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.1016/S2214-109X(18)30247-X
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE



MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Public Health
EISSN 2214-109X
EndPage e757
ExternalDocumentID oai_doaj_org_article_ca924bf962fa410c928c824cf128445b
PMC6005122
29903376
10_1016_S2214_109X_18_30247_X
S2214109X1830247X
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation Bill & Melinda Gates Foundation.
GrantInformation_xml – fundername: Bill & Melinda Gates Foundation
  funderid: http://dx.doi.org/10.13039/100000865
– fundername: NIAID NIH HHS
  grantid: T32 AI007291
GroupedDBID .1-
.FO
0R~
1P~
457
53G
AAEDT
AAEDW
AAIKJ
AALRI
AAMRU
AAXUO
AAYWO
ABMAC
ACGFS
ACHQT
ACVFH
ADBBV
ADCNI
ADEZE
ADVLN
AENEX
AEUPX
AEVXI
AEXQZ
AFPUW
AFRHN
AFTJW
AGHFR
AIGII
AITUG
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
APXCP
BAWUL
BCNDV
DIK
EBS
EJD
FDB
GROUPED_DOAJ
HZ~
IPNFZ
IXB
KQ8
M41
M~E
O9-
OD.
OK1
OO~
RIG
ROL
SSZ
Z5R
0SF
6I.
AACTN
AAFTH
AFCTW
NCXOZ
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c653t-462c345adf4be3e18d3588e3156494f5640e0b9e0f93f76c4739c2690961da993
IEDL.DBID DOA
ISICitedReferencesCount 810
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000435591400022&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2214-109X
IngestDate Fri Oct 03 12:51:37 EDT 2025
Thu Aug 21 18:20:46 EDT 2025
Fri Sep 05 08:25:05 EDT 2025
Mon Jul 21 05:59:41 EDT 2025
Tue Nov 18 22:38:16 EST 2025
Wed Nov 05 20:29:33 EST 2025
Wed May 17 00:08:27 EDT 2023
Tue Aug 26 16:32:30 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Language English
License This is an open access article under the CC BY license.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c653t-462c345adf4be3e18d3588e3156494f5640e0b9e0f93f76c4739c2690961da993
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://doaj.org/article/ca924bf962fa410c928c824cf128445b
PMID 29903376
PQID 2056398447
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_ca924bf962fa410c928c824cf128445b
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6005122
proquest_miscellaneous_2056398447
pubmed_primary_29903376
crossref_citationtrail_10_1016_S2214_109X_18_30247_X
crossref_primary_10_1016_S2214_109X_18_30247_X
elsevier_sciencedirect_doi_10_1016_S2214_109X_18_30247_X
elsevier_clinicalkey_doi_10_1016_S2214_109X_18_30247_X
PublicationCentury 2000
PublicationDate 2018-07-01
PublicationDateYYYYMMDD 2018-07-01
PublicationDate_xml – month: 07
  year: 2018
  text: 2018-07-01
  day: 01
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle The Lancet global health
PublicationTitleAlternate Lancet Glob Health
PublicationYear 2018
Publisher Elsevier Ltd
Elsevier
Publisher_xml – name: Elsevier Ltd
– name: Elsevier
References Knoll, O'Brien, Henkle (bib12) 2009
Lagos, Horwitz, Toro (bib30) 1996; 15
(bib32) 2005
Gessner, Sutanto, Linehan (bib27) 2005; 365
O'Brien, Wolfson, Watt (bib1) 2009; 374
Stevens, Alkema, Black (bib15) 2016; 13
Cernuschi, Furrer, Schwalbe, Jones, Berndt, McAdams (bib44) 2011; 89
Johnson, Deloria-Knoll, Levine (bib37) 2010; 7
Klugman, Madhi, Huebner (bib21) 2003; 349
Madhi, Kuwanda, Cutland, Klugman (bib20) 2005; 40
Lucero, Nohynek, Williams (bib23) 2009; 28
Hammitt, Crane, Karani (bib7) 2016; 4
Kilpi T, Jokinen J, Puumalainen T, et al. Effectiveness of pneumococcal
Black, Shinefield, Ling (bib17) 2002; 21
Lucero, Dulalia, Nillos (bib11) 2009; 4
Feikin, Nelson, Watt, Mohsni, Wenger, Levine (bib13) 2004; 10
Adegbola, Secka, Lahai (bib6) 2005; 366
Walker, Rudan, Liu (bib42) 2013; 381
Baqui, El Arifeen, Saha (bib28) 2007; 26
bib4
Cherian, Mulholland, Carlin (bib33) 2005; 83
Levine, Lagos, Munoz (bib29) 1999; 18
Black, Shinefield, Fireman (bib18) 2000; 19
Ramakrishnan, Moisi, Klugman (bib50) 2010; 10
Pilishvili, Lexau, Farley (bib8) 2010; 201
Chandramohan, Setel, Quigley (bib46) 2001; 30
Qing, Gang, Lin (bib52) 2015; 22
Bonten, Huijts, Bolkenbaas (bib34) 2015; 372
Scott, Berkley, Mwangi (bib49) 2011; 378
protein d conjugate vaccine against radiologically confirmed pneumonia. Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC, USA; Sept 5–9, 2014. G-295b (abstr).
Liu, Oza, Hogan (bib16) 2016; 388
Hansen, Black, Shinefield (bib19) 2006; 25
Soleman, Chandramohan, Shibuya (bib45) 2006; 84
(bib31) 1991
Nair, Simoes, Rudan (bib39) 2013; 381
(bib35) 2016
Tregnaghi, Saez-Llorens, Lopez (bib24) 2014; 11
Russell, Sanderson, Temple, Mulholland (bib36) 2011
Mulholland, Hilton, Adegbola (bib26) 1997; 349
Murray, Shengelia, Gupta, Moussavi, Tandon, Thieren (bib43) 2003; 362
(bib14) 2015
(bib40) 2017; 17
Nunes, von Gottberg, de Gouveia (bib47) 2011; 25
Waight, Andrews, Ladhani, Sheppard, Slack, Miller (bib9) 2015; 15
Feikin, Kagucia, Loo (bib38) 2013; 10
von Gottberg, de Gouveia, Tempia (bib10) 2014; 371
You, Hug, Ejdemyr (bib41) 2015; 386
Murphy, White, Pastor (bib5) 1993; 269
von Mollendorf, von Gottberg, Tempia (bib48) 2015; 60
Cutts, Zaman, Enwere (bib22) 2005; 365
Watt, Wolfson, O'Brien (bib2) 2009; 374
(bib3) 2013
Lin (bib51) 2013; 5
Lucero (10.1016/S2214-109X(18)30247-X_bib11) 2009; 4
(10.1016/S2214-109X(18)30247-X_bib32) 2005
Hansen (10.1016/S2214-109X(18)30247-X_bib19) 2006; 25
Adegbola (10.1016/S2214-109X(18)30247-X_bib6) 2005; 366
Feikin (10.1016/S2214-109X(18)30247-X_bib13) 2004; 10
Stevens (10.1016/S2214-109X(18)30247-X_bib15) 2016; 13
Soleman (10.1016/S2214-109X(18)30247-X_bib45) 2006; 84
Liu (10.1016/S2214-109X(18)30247-X_bib16) 2016; 388
Bonten (10.1016/S2214-109X(18)30247-X_bib34) 2015; 372
Lin (10.1016/S2214-109X(18)30247-X_bib51) 2013; 5
Johnson (10.1016/S2214-109X(18)30247-X_bib37) 2010; 7
Ramakrishnan (10.1016/S2214-109X(18)30247-X_bib50) 2010; 10
Hammitt (10.1016/S2214-109X(18)30247-X_bib7) 2016; 4
Knoll (10.1016/S2214-109X(18)30247-X_bib12) 2009
Walker (10.1016/S2214-109X(18)30247-X_bib42) 2013; 381
Black (10.1016/S2214-109X(18)30247-X_bib17) 2002; 21
Black (10.1016/S2214-109X(18)30247-X_bib18) 2000; 19
von Gottberg (10.1016/S2214-109X(18)30247-X_bib10) 2014; 371
Tregnaghi (10.1016/S2214-109X(18)30247-X_bib24) 2014; 11
Lucero (10.1016/S2214-109X(18)30247-X_bib23) 2009; 28
10.1016/S2214-109X(18)30247-X_bib25
You (10.1016/S2214-109X(18)30247-X_bib41) 2015; 386
Chandramohan (10.1016/S2214-109X(18)30247-X_bib46) 2001; 30
Murphy (10.1016/S2214-109X(18)30247-X_bib5) 1993; 269
Watt (10.1016/S2214-109X(18)30247-X_bib2) 2009; 374
Madhi (10.1016/S2214-109X(18)30247-X_bib20) 2005; 40
Nair (10.1016/S2214-109X(18)30247-X_bib39) 2013; 381
Waight (10.1016/S2214-109X(18)30247-X_bib9) 2015; 15
Nunes (10.1016/S2214-109X(18)30247-X_bib47) 2011; 25
Cutts (10.1016/S2214-109X(18)30247-X_bib22) 2005; 365
Cherian (10.1016/S2214-109X(18)30247-X_bib33) 2005; 83
Cernuschi (10.1016/S2214-109X(18)30247-X_bib44) 2011; 89
(10.1016/S2214-109X(18)30247-X_bib40) 2017; 17
(10.1016/S2214-109X(18)30247-X_bib31) 1991
Pilishvili (10.1016/S2214-109X(18)30247-X_bib8) 2010; 201
Baqui (10.1016/S2214-109X(18)30247-X_bib28) 2007; 26
Scott (10.1016/S2214-109X(18)30247-X_bib49) 2011; 378
Qing (10.1016/S2214-109X(18)30247-X_bib52) 2015; 22
Gessner (10.1016/S2214-109X(18)30247-X_bib27) 2005; 365
Levine (10.1016/S2214-109X(18)30247-X_bib29) 1999; 18
Klugman (10.1016/S2214-109X(18)30247-X_bib21) 2003; 349
Murray (10.1016/S2214-109X(18)30247-X_bib43) 2003; 362
O'Brien (10.1016/S2214-109X(18)30247-X_bib1) 2009; 374
Russell (10.1016/S2214-109X(18)30247-X_bib36) 2011
Feikin (10.1016/S2214-109X(18)30247-X_bib38) 2013; 10
Mulholland (10.1016/S2214-109X(18)30247-X_bib26) 1997; 349
von Mollendorf (10.1016/S2214-109X(18)30247-X_bib48) 2015; 60
Lagos (10.1016/S2214-109X(18)30247-X_bib30) 1996; 15
(10.1016/S2214-109X(18)30247-X_bib14) 2015
29903364 - Lancet Glob Health. 2018 Jul;6(7):e706-e707. doi: 10.1016/S2214-109X(18)30274-2
References_xml – volume: 4
  year: 2009
  ident: bib11
  article-title: Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age
  publication-title: Cochrane Database Syst Rev
– volume: 5
  start-page: 43
  year: 2013
  end-page: 45
  ident: bib51
  article-title: 0–2 age children 2nd type vaccination rate analysis
  publication-title: Chinese Clinical Doctor
– year: 2015
  ident: bib14
  article-title: World population prospects: the 2015 revision
– volume: 89
  start-page: 913
  year: 2011
  end-page: 918
  ident: bib44
  article-title: Advance market commitment for pneumococcal vaccines: putting theory into practice
  publication-title: Bull World Health Organ
– volume: 269
  start-page: 246
  year: 1993
  end-page: 248
  ident: bib5
  article-title: Declining incidence of
  publication-title: JAMA
– volume: 388
  start-page: 3027
  year: 2016
  end-page: 3035
  ident: bib16
  article-title: Global, regional, and national causes of under-5 mortality in 2000–15: an updated systematic analysis with implications for the Sustainable Development Goals
  publication-title: Lancet
– volume: 7
  start-page: e1000348
  year: 2010
  ident: bib37
  article-title: Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project
  publication-title: PLoS Med
– volume: 372
  start-page: 1114
  year: 2015
  end-page: 1125
  ident: bib34
  article-title: Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults
  publication-title: N Engl J Med
– volume: 386
  start-page: 2275
  year: 2015
  end-page: 2286
  ident: bib41
  article-title: Global, regional, and national levels and trends in under-5 mortality between 1990 and 2015, with scenario-based projections to 2030: a systematic analysis by the UN Inter-agency Group for Child Mortality Estimation
  publication-title: Lancet
– ident: bib4
  article-title: VIEW-hub
– volume: 349
  start-page: 1191
  year: 1997
  end-page: 1217
  ident: bib26
  article-title: Randomised trial of
  publication-title: Lancet
– volume: 60
  start-page: 1346
  year: 2015
  end-page: 1356
  ident: bib48
  article-title: Increased risk for and mortality from invasive pneumococcal disease in hiv-exposed but uninfected infants aged <1 year in South Africa, 2009–2013
  publication-title: Clin Infect Dis
– year: 2009
  ident: bib12
  article-title: Global literature review of
– reference: Kilpi T, Jokinen J, Puumalainen T, et al. Effectiveness of pneumococcal
– volume: 25
  start-page: 779
  year: 2006
  end-page: 781
  ident: bib19
  article-title: Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs
  publication-title: Pediatr Infect Dis J
– volume: 366
  start-page: 144
  year: 2005
  end-page: 150
  ident: bib6
  article-title: Elimination of
  publication-title: Lancet
– volume: 30
  start-page: 509
  year: 2001
  end-page: 514
  ident: bib46
  article-title: Effect of misclassification of causes of death in verbal autopsy: can it be adjusted?
  publication-title: Int J Epidemiol
– volume: 22
  start-page: 322
  year: 2015
  end-page: 323
  ident: bib52
  article-title: District local and mobile children 1st and 2nd type vaccination situation survey and analysis
  publication-title: Applied Preventive Healthcare
– volume: 10
  start-page: 329
  year: 2010
  end-page: 337
  ident: bib50
  article-title: Increased risk of invasive bacterial infections in African people with sickle-cell disease: a systematic review and meta-analysis
  publication-title: Lancet Infect Dis
– volume: 4
  start-page: e185
  year: 2016
  end-page: e194
  ident: bib7
  article-title: Effect of
  publication-title: Lancet Glob Health
– volume: 19
  start-page: 187
  year: 2000
  end-page: 195
  ident: bib18
  article-title: Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
  publication-title: Pediatr Infect Dis J
– volume: 17
  start-page: 1133
  year: 2017
  end-page: 1161
  ident: bib40
  article-title: Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015
  publication-title: Lancet Infect Dis
– volume: 10
  start-page: 1270
  year: 2004
  end-page: 1276
  ident: bib13
  article-title: Rapid assessment tool for
  publication-title: Emerg infect Dis
– volume: 374
  start-page: 893
  year: 2009
  end-page: 902
  ident: bib1
  article-title: Burden of disease caused by
  publication-title: Lancet
– reference: protein d conjugate vaccine against radiologically confirmed pneumonia. Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC, USA; Sept 5–9, 2014. G-295b (abstr).
– volume: 378
  start-page: 1316
  year: 2011
  end-page: 1323
  ident: bib49
  article-title: Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study
  publication-title: Lancet
– volume: 18
  start-page: 1060
  year: 1999
  end-page: 1064
  ident: bib29
  article-title: Defining the burden of pneumonia in children preventable by vaccination against
  publication-title: Pediatr Infect Dis J
– volume: 15
  start-page: 216
  year: 1996
  end-page: 222
  ident: bib30
  article-title: Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: practicality and effectiveness in preventing invasive
  publication-title: Pediatr Infect Dis J
– volume: 371
  start-page: 1889
  year: 2014
  end-page: 1899
  ident: bib10
  article-title: Effects of vaccination on invasive pneumococcal disease in South Africa
  publication-title: N Engl J Med
– volume: 374
  start-page: 903
  year: 2009
  end-page: 911
  ident: bib2
  article-title: Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates
  publication-title: Lancet
– volume: 381
  start-page: 1405
  year: 2013
  end-page: 1416
  ident: bib42
  article-title: Global burden of childhood pneumonia and diarrhoea
  publication-title: Lancet
– volume: 26
  start-page: 565
  year: 2007
  end-page: 571
  ident: bib28
  article-title: Effectiveness of
  publication-title: Pediatr Infect Dis J
– volume: 201
  start-page: 32
  year: 2010
  end-page: 41
  ident: bib8
  article-title: Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine
  publication-title: J Infect Dis
– volume: 365
  start-page: 1139
  year: 2005
  end-page: 1146
  ident: bib22
  article-title: Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial
  publication-title: Lancet
– year: 2016
  ident: bib35
  article-title: Immunization, vaccines and biologicals. Data, statistics, and graphics. WHO and UNICEF estimates of national immunization coverage
– volume: 84
  start-page: 239
  year: 2006
  end-page: 245
  ident: bib45
  article-title: Verbal autopsy: current practices and challenges
  publication-title: Bull World Health Organ
– volume: 40
  start-page: 1511
  year: 2005
  end-page: 1518
  ident: bib20
  article-title: The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children
  publication-title: Clin Infect Dis
– volume: 13
  start-page: e1002056
  year: 2016
  ident: bib15
  article-title: Guidelines for accurate and transparent health estimates reporting: the GATHER statement
  publication-title: PLoS Med
– volume: 28
  start-page: 455
  year: 2009
  end-page: 462
  ident: bib23
  article-title: Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines: a randomized, double-blind, placebo-controlled trial
  publication-title: Pediatr Infect Dis J
– volume: 362
  start-page: 1022
  year: 2003
  end-page: 1027
  ident: bib43
  article-title: Validity of reported vaccination coverage in 45 countries
  publication-title: Lancet
– volume: 349
  start-page: 1341
  year: 2003
  end-page: 1348
  ident: bib21
  article-title: A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection
  publication-title: N Engl J Med
– volume: 83
  start-page: 353
  year: 2005
  end-page: 359
  ident: bib33
  article-title: Standardized interpretation of paediatric chest radiographs for the diagnosis of pneumonia in epidemiological studies
  publication-title: Bull World Health Organ
– volume: 10
  start-page: e1001517
  year: 2013
  ident: bib38
  article-title: Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites
  publication-title: PLoS Med
– volume: 21
  start-page: 810
  year: 2002
  end-page: 815
  ident: bib17
  article-title: Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia
  publication-title: Pediatr Infect Dis J
– volume: 381
  start-page: 1380
  year: 2013
  end-page: 1390
  ident: bib39
  article-title: Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis
  publication-title: Lancet
– year: 1991
  ident: bib31
  article-title: Programme for the control of acute respiratory infections: technical bases for the WHO recommendations on the management of pneumonia in children at first level health facilities
– volume: 15
  start-page: 629
  year: 2015
  ident: bib9
  article-title: Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study
  publication-title: Lancet Infect Dis
– year: 2011
  ident: bib36
  article-title: Global review of the distribution of pneumococcal disease by age and region
– year: 2005
  ident: bib32
  article-title: Handbook IMCI: integrated management of childhood illness
– volume: 25
  start-page: 453
  year: 2011
  end-page: 462
  ident: bib47
  article-title: The impact of antiretroviral treatment on the burden of invasive pneumococcal disease in South African children: a time series analysis
  publication-title: AIDS
– volume: 365
  start-page: 43
  year: 2005
  end-page: 52
  ident: bib27
  article-title: Incidences of vaccine-preventable
  publication-title: Lancet
– volume: 11
  start-page: e1001657
  year: 2014
  ident: bib24
  article-title: Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial
  publication-title: PLoS Med
– year: 2013
  ident: bib3
  article-title: Estimated Hib and pneumococcal deaths for children under 5 years of age, 2008
– volume: 349
  start-page: 1341
  year: 2003
  ident: 10.1016/S2214-109X(18)30247-X_bib21
  article-title: A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa035060
– volume: 366
  start-page: 144
  year: 2005
  ident: 10.1016/S2214-109X(18)30247-X_bib6
  article-title: Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study
  publication-title: Lancet
  doi: 10.1016/S0140-6736(05)66788-8
– volume: 22
  start-page: 322
  year: 2015
  ident: 10.1016/S2214-109X(18)30247-X_bib52
  article-title: District local and mobile children 1st and 2nd type vaccination situation survey and analysis
  publication-title: Applied Preventive Healthcare
– ident: 10.1016/S2214-109X(18)30247-X_bib25
– volume: 25
  start-page: 453
  year: 2011
  ident: 10.1016/S2214-109X(18)30247-X_bib47
  article-title: The impact of antiretroviral treatment on the burden of invasive pneumococcal disease in South African children: a time series analysis
  publication-title: AIDS
  doi: 10.1097/QAD.0b013e328341b7f1
– volume: 374
  start-page: 903
  year: 2009
  ident: 10.1016/S2214-109X(18)30247-X_bib2
  article-title: Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates
  publication-title: Lancet
  doi: 10.1016/S0140-6736(09)61203-4
– volume: 10
  start-page: e1001517
  year: 2013
  ident: 10.1016/S2214-109X(18)30247-X_bib38
  article-title: Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites
  publication-title: PLoS Med
  doi: 10.1371/journal.pmed.1001517
– volume: 269
  start-page: 246
  year: 1993
  ident: 10.1016/S2214-109X(18)30247-X_bib5
  article-title: Declining incidence of Haemophilus influenzae type b disease since introduction of vaccination
  publication-title: JAMA
  doi: 10.1001/jama.1993.03500020080036
– volume: 388
  start-page: 3027
  year: 2016
  ident: 10.1016/S2214-109X(18)30247-X_bib16
  article-title: Global, regional, and national causes of under-5 mortality in 2000–15: an updated systematic analysis with implications for the Sustainable Development Goals
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)31593-8
– volume: 362
  start-page: 1022
  year: 2003
  ident: 10.1016/S2214-109X(18)30247-X_bib43
  article-title: Validity of reported vaccination coverage in 45 countries
  publication-title: Lancet
  doi: 10.1016/S0140-6736(03)14411-X
– volume: 4
  year: 2009
  ident: 10.1016/S2214-109X(18)30247-X_bib11
  article-title: Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age
  publication-title: Cochrane Database Syst Rev
– volume: 371
  start-page: 1889
  year: 2014
  ident: 10.1016/S2214-109X(18)30247-X_bib10
  article-title: Effects of vaccination on invasive pneumococcal disease in South Africa
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1401914
– volume: 11
  start-page: e1001657
  year: 2014
  ident: 10.1016/S2214-109X(18)30247-X_bib24
  article-title: Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial
  publication-title: PLoS Med
  doi: 10.1371/journal.pmed.1001657
– volume: 349
  start-page: 1191
  year: 1997
  ident: 10.1016/S2214-109X(18)30247-X_bib26
  article-title: Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine for prevention of pneumonia and meningitis in Gambian infants
  publication-title: Lancet
  doi: 10.1016/S0140-6736(96)09267-7
– volume: 7
  start-page: e1000348
  year: 2010
  ident: 10.1016/S2214-109X(18)30247-X_bib37
  article-title: Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project
  publication-title: PLoS Med
  doi: 10.1371/journal.pmed.1000348
– year: 2005
  ident: 10.1016/S2214-109X(18)30247-X_bib32
– volume: 21
  start-page: 810
  year: 2002
  ident: 10.1016/S2214-109X(18)30247-X_bib17
  article-title: Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia
  publication-title: Pediatr Infect Dis J
  doi: 10.1097/00006454-200209000-00005
– volume: 381
  start-page: 1405
  year: 2013
  ident: 10.1016/S2214-109X(18)30247-X_bib42
  article-title: Global burden of childhood pneumonia and diarrhoea
  publication-title: Lancet
  doi: 10.1016/S0140-6736(13)60222-6
– volume: 374
  start-page: 893
  year: 2009
  ident: 10.1016/S2214-109X(18)30247-X_bib1
  article-title: Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates
  publication-title: Lancet
  doi: 10.1016/S0140-6736(09)61204-6
– volume: 15
  start-page: 629
  year: 2015
  ident: 10.1016/S2214-109X(18)30247-X_bib9
  article-title: Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(15)70044-7
– volume: 10
  start-page: 1270
  year: 2004
  ident: 10.1016/S2214-109X(18)30247-X_bib13
  article-title: Rapid assessment tool for Haemophilus influenzae type b disease in developing countries
  publication-title: Emerg infect Dis
  doi: 10.3201/eid1007.030737
– volume: 386
  start-page: 2275
  year: 2015
  ident: 10.1016/S2214-109X(18)30247-X_bib41
  article-title: Global, regional, and national levels and trends in under-5 mortality between 1990 and 2015, with scenario-based projections to 2030: a systematic analysis by the UN Inter-agency Group for Child Mortality Estimation
  publication-title: Lancet
  doi: 10.1016/S0140-6736(15)00120-8
– year: 2011
  ident: 10.1016/S2214-109X(18)30247-X_bib36
– volume: 10
  start-page: 329
  year: 2010
  ident: 10.1016/S2214-109X(18)30247-X_bib50
  article-title: Increased risk of invasive bacterial infections in African people with sickle-cell disease: a systematic review and meta-analysis
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(10)70055-4
– year: 2015
  ident: 10.1016/S2214-109X(18)30247-X_bib14
– volume: 4
  start-page: e185
  year: 2016
  ident: 10.1016/S2214-109X(18)30247-X_bib7
  article-title: Effect of Haemophilus influenzae type b vaccination without a booster dose on invasive H influenzae type b disease, nasopharyngeal carriage, and population immunity in Kilifi, Kenya: a 15-year regional surveillance study
  publication-title: Lancet Glob Health
  doi: 10.1016/S2214-109X(15)00316-2
– volume: 26
  start-page: 565
  year: 2007
  ident: 10.1016/S2214-109X(18)30247-X_bib28
  article-title: Effectiveness of Haemophilus influenzae type B conjugate vaccine on prevention of pneumonia and meningitis in Bangladeshi children: a case-control study
  publication-title: Pediatr Infect Dis J
  doi: 10.1097/INF.0b013e31806166a0
– year: 1991
  ident: 10.1016/S2214-109X(18)30247-X_bib31
– volume: 365
  start-page: 1139
  year: 2005
  ident: 10.1016/S2214-109X(18)30247-X_bib22
  article-title: Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(05)71876-6
– volume: 201
  start-page: 32
  year: 2010
  ident: 10.1016/S2214-109X(18)30247-X_bib8
  article-title: Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine
  publication-title: J Infect Dis
  doi: 10.1086/648593
– volume: 372
  start-page: 1114
  year: 2015
  ident: 10.1016/S2214-109X(18)30247-X_bib34
  article-title: Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1408544
– volume: 89
  start-page: 913
  year: 2011
  ident: 10.1016/S2214-109X(18)30247-X_bib44
  article-title: Advance market commitment for pneumococcal vaccines: putting theory into practice
  publication-title: Bull World Health Organ
  doi: 10.2471/BLT.11.087700
– volume: 365
  start-page: 43
  year: 2005
  ident: 10.1016/S2214-109X(18)30247-X_bib27
  article-title: Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(04)17664-2
– volume: 15
  start-page: 216
  year: 1996
  ident: 10.1016/S2214-109X(18)30247-X_bib30
  article-title: Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections
  publication-title: Pediatr Infect Dis J
  doi: 10.1097/00006454-199603000-00008
– volume: 30
  start-page: 509
  year: 2001
  ident: 10.1016/S2214-109X(18)30247-X_bib46
  article-title: Effect of misclassification of causes of death in verbal autopsy: can it be adjusted?
  publication-title: Int J Epidemiol
  doi: 10.1093/ije/30.3.509
– volume: 381
  start-page: 1380
  year: 2013
  ident: 10.1016/S2214-109X(18)30247-X_bib39
  article-title: Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis
  publication-title: Lancet
  doi: 10.1016/S0140-6736(12)61901-1
– volume: 5
  start-page: 43
  year: 2013
  ident: 10.1016/S2214-109X(18)30247-X_bib51
  article-title: 0–2 age children 2nd type vaccination rate analysis
  publication-title: Chinese Clinical Doctor
– year: 2009
  ident: 10.1016/S2214-109X(18)30247-X_bib12
– volume: 40
  start-page: 1511
  year: 2005
  ident: 10.1016/S2214-109X(18)30247-X_bib20
  article-title: The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children
  publication-title: Clin Infect Dis
  doi: 10.1086/429828
– volume: 19
  start-page: 187
  year: 2000
  ident: 10.1016/S2214-109X(18)30247-X_bib18
  article-title: Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
  publication-title: Pediatr Infect Dis J
  doi: 10.1097/00006454-200003000-00003
– volume: 25
  start-page: 779
  year: 2006
  ident: 10.1016/S2214-109X(18)30247-X_bib19
  article-title: Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs
  publication-title: Pediatr Infect Dis J
  doi: 10.1097/01.inf.0000232706.35674.2f
– volume: 18
  start-page: 1060
  year: 1999
  ident: 10.1016/S2214-109X(18)30247-X_bib29
  article-title: Defining the burden of pneumonia in children preventable by vaccination against Haemophilus influenzae type b
  publication-title: Pediatr Infect Dis J
  doi: 10.1097/00006454-199912000-00006
– volume: 28
  start-page: 455
  year: 2009
  ident: 10.1016/S2214-109X(18)30247-X_bib23
  article-title: Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines: a randomized, double-blind, placebo-controlled trial
  publication-title: Pediatr Infect Dis J
  doi: 10.1097/INF.0b013e31819637af
– volume: 17
  start-page: 1133
  year: 2017
  ident: 10.1016/S2214-109X(18)30247-X_bib40
  article-title: Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(17)30396-1
– volume: 60
  start-page: 1346
  year: 2015
  ident: 10.1016/S2214-109X(18)30247-X_bib48
  article-title: Increased risk for and mortality from invasive pneumococcal disease in hiv-exposed but uninfected infants aged <1 year in South Africa, 2009–2013
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/civ059
– volume: 84
  start-page: 239
  year: 2006
  ident: 10.1016/S2214-109X(18)30247-X_bib45
  article-title: Verbal autopsy: current practices and challenges
  publication-title: Bull World Health Organ
  doi: 10.2471/BLT.05.027003
– volume: 83
  start-page: 353
  year: 2005
  ident: 10.1016/S2214-109X(18)30247-X_bib33
  article-title: Standardized interpretation of paediatric chest radiographs for the diagnosis of pneumonia in epidemiological studies
  publication-title: Bull World Health Organ
– volume: 378
  start-page: 1316
  year: 2011
  ident: 10.1016/S2214-109X(18)30247-X_bib49
  article-title: Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study
  publication-title: Lancet
  doi: 10.1016/S0140-6736(11)60888-X
– volume: 13
  start-page: e1002056
  year: 2016
  ident: 10.1016/S2214-109X(18)30247-X_bib15
  article-title: Guidelines for accurate and transparent health estimates reporting: the GATHER statement
  publication-title: PLoS Med
  doi: 10.1371/journal.pmed.1002056
– reference: 29903364 - Lancet Glob Health. 2018 Jul;6(7):e706-e707. doi: 10.1016/S2214-109X(18)30274-2
SSID ssj0000993277
Score 2.646512
Snippet Pneumococcal conjugate vaccine (PCV) and Haemophilus influenzae type b (Hib) vaccine are now used in most countries. To monitor global and regional progress...
Background: Pneumococcal conjugate vaccine (PCV) and Haemophilus influenzae type b (Hib) vaccine are now used in most countries. To monitor global and regional...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
elsevier
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage e744
SubjectTerms Child, Preschool
Global Health - statistics & numerical data
Haemophilus Infections - epidemiology
Haemophilus influenzae type b
Humans
Infant
Pneumococcal Infections - epidemiology
Streptococcus pneumoniae
Vaccines, Conjugate
Title Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15
URI https://www.clinicalkey.com/#!/content/1-s2.0-S2214109X1830247X
https://dx.doi.org/10.1016/S2214-109X(18)30247-X
https://www.ncbi.nlm.nih.gov/pubmed/29903376
https://www.proquest.com/docview/2056398447
https://pubmed.ncbi.nlm.nih.gov/PMC6005122
https://doaj.org/article/ca924bf962fa410c928c824cf128445b
Volume 6
WOSCitedRecordID wos000435591400022&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2214-109X
  dateEnd: 20231231
  omitProxy: false
  ssIdentifier: ssj0000993277
  issn: 2214-109X
  databaseCode: DOA
  dateStart: 20130101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2214-109X
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000993277
  issn: 2214-109X
  databaseCode: M~E
  dateStart: 20130101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELag4oCEEP-En8pIHEBq6MZ2HJsboFa9UCEBUm6R49hqqjZZ7W564FD1HXgSXoknYSZOwi4clgOXaBWvHTn-MvONxzNDyMsZt8ZkFY9lWcpYpGUSl4yVsQZ14TNQiFqFYhPZ8bHKc_1prdQXngkL6YHDi9u3BiyE0mvJvBHJzGqmrGLCehSsMDZKX2A9a8bUaeA9nPVlFxlLBMganf8O39n_PN18lajXHNRUFucbiqnP37-hn_7mn38eo1zTS4d3yO2BUNJ3YSJ3yTXX3CO3wm4cDUFG98mPEK1AW0_RDT1ftSAHbbek88Z1AMTaOGqaih4Zd97OT-ozaKpD-ZJv0IT7tLSkgzMHWugYA46_gUJStzA4OBjXpx1uzNELY9Flv3xLQ8qRPYolIJD27_VPGjchKWb5OEfCS4E-Uwzp-Xn1PUkfkK-HB18-HMVDsYbYypSvYiGZ5SI1lRel4y5RFU-VchyT0Wjh4Tpzs1K7mdfcZ9KKjGvLwDbXMqkMLNdDstO0jXtMqOTWKu4qIHNaGFmqCsxU4zNuXOqBUUZEjCtV2CGTORbUOCumI2u4wOhcz4tEFf0CF3lE3kzd5iGVx7YO7xEG058xE3d_A_BZDPgstuEzInIEUTEGu4J4hoHqbU9XU8eBDQWW8y9dX4xoLUBaoAvINK7tlgUDvgufnxBZRB4F9E7TQ2LCQd9EJNvA9cb8N1ua-qTPSC5RtjP25H-8sKfkJpBSFY5EPyM7q0XnnpMb9mJVLxe75HqWq93-Y4frx8uDX-alVHY
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Burden+of+Streptococcus+pneumoniae+and+Haemophilus+influenzae+type+b+disease+in+children+in+the+era+of+conjugate+vaccines%3A+global%2C+regional%2C+and+national+estimates+for+2000%E2%80%9315&rft.jtitle=The+Lancet+global+health&rft.au=Wahl%2C+Brian&rft.au=O%27Brien%2C+Katherine+L&rft.au=Greenbaum%2C+Adena&rft.au=Majumder%2C+Anwesha&rft.date=2018-07-01&rft.pub=Elsevier+Ltd&rft.issn=2214-109X&rft.eissn=2214-109X&rft.volume=6&rft.issue=7&rft.spage=e744&rft.epage=e757&rft_id=info:doi/10.1016%2FS2214-109X%2818%2930247-X&rft.externalDocID=S2214109X1830247X
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2214-109X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2214-109X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2214-109X&client=summon